Xilio Therapeutics, Inc. (XLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
XLO Stock Price Chart Interactive Chart >
XLO Price/Volume Stats
| Current price | $3.65 | 52-week high | $14.86 |
| Prev. close | $3.97 | 52-week low | $1.95 |
| Day low | $3.50 | Volume | 144,667 |
| Day high | $4.07 | Avg. volume | 97,423 |
| 50-day MA | $2.67 | Dividend yield | N/A |
| 200-day MA | $2.81 | Market Cap | 100.27M |
Xilio Therapeutics, Inc. (XLO) Company Bio
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Latest XLO News From Around the Web
Below are the latest news stories about XILIO THERAPEUTICS INC that investors may wish to consider to help them evaluate XLO as an investment opportunity.
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of |
Xilio Therapeutics (XLO) Investor Presentation - Slideshow (NASDAQ:XLO)The following slide deck was published by Xilio Therapeutics, Inc. |
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial ResultsXTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome |
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ SummitWALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutic |
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceWALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET. |
XLO Price Returns
| 1-mo | 35.69% |
| 3-mo | 59.39% |
| 6-mo | 21.26% |
| 1-year | -73.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 35.69% |
| 2022 | -83.19% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...